Cerus Corporation is heading into its August earnings window with short interest running at a multi-month high — even as the stock posts its best weekly gain in some time and options traders turn unmistakably bullish.
The short interest story demands attention this week. Short interest surged 66% in a single week, jumping from roughly 10.9 million shares to 18.1 million — pushing the short position to 9.4% of the free float, the highest level in at least 30 days and nearly double the reading from late May. That move follows a quieter stretch in mid-June when shorts pulled back to around 10.8 million shares; the sharp re-entry on June 25 stands out. FINRA's fortnightly settlement data corroborates the trend, pegging official short shares at 19.7 million with a days-to-cover of 8.5 — a meaningful overhang for a stock trading at $2.92.
The borrow market tells a subtler story, and it's where the tension sits. Despite the short interest spike, availability remains extraordinarily loose — roughly 2,847% of short interest in shares available to borrow, far above even the 52-week floor of 457%. That means shorts face essentially no squeeze pressure from the lending pool; there are nearly 100 million shares available to borrow against an 18 million share short position. Cost to borrow has ticked up 48% over the week to 0.44%, but that's still a low absolute rate — the borrow is cheap and easy. The ORTEX short score jumped sharply to 55.3 on June 25 from 44.3 the prior day, its highest reading in the data window, confirming the sudden shift in bearish positioning. Yet because the underlying lending market is so loose, the setup looks more like a fresh short build than a squeeze-in-progress.
Options traders are pulling hard in the opposite direction. The put/call ratio has dropped to 0.11, about 1.6 standard deviations below its 20-day average — making this one of the more call-heavy readings of the past year and placing it near the lower end of the 52-week range of 0.04 to 0.44. That call bias has been building steadily since late May, when the PCR was running above 0.14. The stock's 8% weekly gain reinforces the divergence: bulls are using the options market, bears are using the borrow market, and both sides are leaning in simultaneously.
The analyst backdrop offers modest support for the bull case. BTIG upgraded CERS to Buy in early May, assigning a $4.00 target — roughly 37% above the current price. Three analysts hold Buy or equivalent ratings with no active bearish coverage, and the consensus sits at Buy. However, the most recent consensus data is 19 days old, slightly past the freshness threshold, and older targets on file — including a Stifel Buy at $3.00 set in late 2024 — suggest the Street has been trimming ambitions over time. The $4.00 BTIG target is directionally consistent with the current price and passes a basic sanity check. Factor scores are mixed: momentum is the clear bright spot, but EPS momentum ranks in the bottom 3rd percentile over 30 days and EPS surprise sits in the 18th percentile, flagging persistent fundamental drag.
Institutional positioning adds context. ARK Investment Management added nearly 961,000 shares in its most recent reported period, holding 9.6% of shares outstanding. Soleus Capital disclosed a position of 5.4% built almost entirely in Q1, a striking near-10 million share initiation. Against that backdrop, insider activity runs the other way — the COO has sold in three separate transactions since March, and the CEO and CFO both sold in a coordinated cluster on March 12. Net insider selling over 90 days totals roughly 1.5 million in value. The insider selling is not unusual for executives at a biotech trading near multi-year lows, but it does provide a contrast to the active managers buying.
The next scheduled earnings event is August 3. After the April 30 print, CERS jumped 42% the following day and held a 36% gain through the five-day window — the most dramatic single-print reaction in the recent history. The June 2 print moved the other way, with a 6% one-day drop deepening to a 9% five-day loss. With the short position now rebuilt to near its highest level in months and call buyers active in the options market, the August 3 release is the obvious flashpoint — the question of what drove the fresh short build and whether the catalyst is known or speculative is worth watching closely into that date.
See the live data behind this article on ORTEX.
Open CERS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
